<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843215</url>
  </required_header>
  <id_info>
    <org_study_id>E20210171</org_study_id>
    <nct_id>NCT04843215</nct_id>
  </id_info>
  <brief_title>A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer</brief_title>
  <official_title>A Phase III, Multicenter, Prospective, Randomized, Controlled Clinical Trial Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer (TOP-GC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changzhi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital of Air Force Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Kunming Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinjiang Medical University Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University Cancer Hosptial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multicenter, prospective, randomized, controlled clinical trial to&#xD;
      evaluate the impact of omentectomy for advanced gastric cancer on patient survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to evaluate the impact of omentectomy for advanced gastric cancer on patient&#xD;
      survival, we designed this trial. Patients who received curative gastrectomy were divided&#xD;
      into two groups based on whether they underwent omentectomy. The purpose of this study is to&#xD;
      prove the non-inferiority of omentum preservation compared with omentectomy in patients with&#xD;
      T3-T4a gastric cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival(DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Disease Free Survivalof the Participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Survival of the Participants</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The volume of intraoperative blood loss</measure>
    <time_frame>1 week</time_frame>
    <description>The volume of intraoperative blood loss (IBL) was defined as the total from suction and the weight of gauze sponges at the conclusion of the operation. The Blood loss volume is recorded in milliliters.</description>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative morbidity</measure>
    <time_frame>1 month</time_frame>
    <description>Postoperative morbidity was defined as the incidence rate of the postoperative complication. The postoperative morbidity were examined within 30 days after surgery. Postoperative morbidity was graded with use of the modified Clavien-Dindo classification of surgical complications.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group/D2 radical gastrectomy with partial omentectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Partial omentectomy with preservation of the greater omentum at &gt;3 cm from the gastroepiploic arcade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group/D2 radical gastrectomy with total omentectom</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group with total omentectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Type of omentectomy</intervention_name>
    <description>Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at &gt;3 cm from the gastroepiploic arcade.Control group with total omentectomy.</description>
    <arm_group_label>Experimental group/D2 radical gastrectomy with partial omentectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Had been treated with Radical resection (D2, R0) of gastric cancer (Lymph node≥16);&#xD;
&#xD;
          2. Physical condition and organ function allows to tolerable abdominal surgery;&#xD;
&#xD;
          3. Willing and able to comply with the program during the study period;&#xD;
&#xD;
          4. Written informed consent provided;&#xD;
&#xD;
          5. ≥ 18 and ≤ 70 years of age; preoperative gastric cancer patients with pathologically&#xD;
             confirmed;&#xD;
&#xD;
          6. With more than a 6-month life expectancy;&#xD;
&#xD;
          7. No other serious concomitant diseases; Sufficient organ functions;&#xD;
&#xD;
          8. No previous history of chemotherapy or radiotherapy;&#xD;
&#xD;
          9. All patients accept 8 cycles XELOX chemotherapy regimen;&#xD;
&#xD;
         10. Clinical stage: T3-4aN0-+M0; 11 . Macroscopic types :Borrmann I-III;&#xD;
&#xD;
        12. Not greater curvature tumor; with distal or total gastrectomy； 13. No previous surgery&#xD;
        for any abdominal disease, except an appendectomy for appendicitis, a laparoscopic&#xD;
        cholecystectomy for gallbladder stones; No previous history of peritonitis, pancreatitis;&#xD;
        14. Karnofsky performance status (KPS)&gt;60; Eastern Cooperative Oncology Group Performance&#xD;
        Status (ECOG): 0-1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnancy or breast feeding; 2. Patients with Serious liver disease (such as cirrhosis,&#xD;
        etc.), kidney disease, respiratory disease or uncontrolled diabetes, hypertension and other&#xD;
        chronic systemic diseases, heart disease with Clinical symptoms, such as congestive heart&#xD;
        failure, coronary heart disease symptoms, drug is difficult to control arrhythmia,&#xD;
        hypertension, or six months had a myocardial infarction attack, or cardiac insufficiency;&#xD;
        3. Organ transplantation patients need immunosuppressive therapy; 4. Severe recurrent&#xD;
        infections were not controlled or with other serious concomitant diseases; 5. Patients got&#xD;
        other primary malignant tumors (except curable skin basal cell carcinoma and cervical&#xD;
        cancer in situ) except gastric cancer within 5 years; 6. Psychiatric disease which require&#xD;
        treatment; 7. Have the history of organ transplantation; 8. Within 6 months before study&#xD;
        starts and in the process of this study, patients participate in other clinical researches.&#xD;
        9. Advanced gastric cancer with omentum invasion 10. Patients can't treated with XELOX&#xD;
        after surgery; 11 . Macroscopic types : Borrmann IV; 12. Tumor invasion of adjacent organ&#xD;
        (T4b) or with distant metastasis#M1 #; 13. Tumor invasion the greater curvature invasion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Han Liang, Master</last_name>
    <phone>+86 022 233401 23</phone>
    <phone_ext>1061</phone_ext>
    <email>tjlianghan@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bik Ke, Doctor</last_name>
    <phone>+86 022 23340123</phone>
    <phone_ext>1061</phone_ext>
    <email>binke@tmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Han</last_name>
      <phone>086-022-23340123</phone>
      <phone_ext>1061</phone_ext>
      <email>tjlianghan@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Omentectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

